CSIMarket Company Name, Ticker, Customers, else..
 
Arrivent Biopharma inc   (NASDAQ: AVBP)
 
Price: $28.3700 $-0.33 -1.150%
Day's High: $29.209999084472656 Week Perf: -8.34 %
Day's Low: $ 28.20 30 Day Perf: -9.82 %
Volume (M): 186,818 52 Wk High: $ 35.83
Volume (M$): $ 0 52 Wk Avg: $25.35
Open: $29.16 52 Wk Low: $17.00



 Market Capitalization (Millions $) 1,351
 Shares Outstanding (Millions) 48
 Employees 77
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -164
 Cash Flow (TTM) (Millions $) -51
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a clinical-stage biopharmaceutical firm focused on identifying, developing, and commercializing medicines for cancer patients. Its lead product candidate, firmonertinib, is being evaluated in multiple clinical trials for non-small cell lung cancer with EGFR mutations. The company is also developing a pipeline of novel therapeutics, including next-generation antibody drug conjugates such as ARR-217 (MRG007).


   Company Address: 18 Campus Boulevard Suite 100 Newtown Square 19073 PA
   Company Phone Number: 277-4836   Stock Exchange / Ticker: NASDAQ AVBP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ   -3.42%    
MRK   -5.04%    
PFE   -4.46%    
TEVA   -1.47%    
VRTX   -8.07%    
VTRS   -2.95%    
• View Complete Report
   



Clinical Study

At the 2024 World Conference on Lung Cancer, ArriVent BioPharma presented compelling interim da...

Published Mon, Sep 9 2024 4:05 PM UTC

Title : Promising Phase 1b Data Elevates ArriVent s Firmonertinib as a Leading Candidate for EGFR PACC Mutant NSCLCAt the 2024 World Conference on Lung Cancer, ArriVent BioPharma presented compelling interim data from their global Phase 1b trial, showcasing the efficacy of Firmonertinib a selective EGFR inhibitor designed for patients with EGFR PACC mutant non-small cell lun...
Product Service News

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Published Wed, Jun 5 2024 11:00 AM UTC

Overview of ArriVent and Alphamab s Multi-Target ADC CollaborationIn a groundbreaking development within the pharmaceutical industry, ArriVent has recently announced a strategic collaboration with Alphamab. This partnership aims to leverage Alphamab s advanced antibody-drug conjugate (ADC) research and discovery platform in conjunction with ArriVent s global expertise in d...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 3.68
PEG (TTM) -

Financial Strength Current
Quick Ratio 13.41
Working Capital Ratio 14.26
Leverage Ratio (MRQ) 0.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.76 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 7.84 $
Book Value 7.71 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,126,429
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.